Is Ansa Biotechnologies, Inc. a real, registered company?
Ansa Biotechnologies, Inc. is a registered filer with the SEC (CIK 1816722) and has filed since 2025-10-02. 2 filings are on record, the latest on 2025-12-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has Ansa Biotechnologies, Inc. raised?
Its new offerings report $45.20M sold across 1 offering, as its own filings state.
Run the free check on Ansa Biotechnologies, Inc. →
EMERYVILLE, CALIFORNIA
Biotechnology
2
$45.20M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2025-12-10 | Amendment first sale 2024-06-28 | $46.45M | $56.93M | SEC filing |
| 2025-10-02 | New offering first sale 2024-06-28 | $45.20M | $55.48M | SEC filing |
Keep reading
More on Ansa Biotechnologies, Inc. and the records around it.
Ansa Biotechnologies, Inc. elsewhere on the record
- Form D filing Oct 2025
Watch Ansa Biotechnologies, Inc.
Get an email when Ansa Biotechnologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Ansa Biotechnologies, Inc.?
Who to contact
- Jason Gammack — Executive Officer, Director
- Daniel Lin-Arlow — Executive Officer, Director
- Yanniv Dorone — Director
- Matthew McManus — Director
- Chenny Zhang — Director
- Sebastian Palluk — Executive Officer
- Round: Form D/A (amended) filed 2025-12-10
- Amount sold: $46.45M
- Industry: Biotechnology
- Based: EMERYVILLE, CALIFORNIA
People listed
- Jason Gammack — Executive Officer, Director
- Daniel Lin-Arlow — Executive Officer, Director
- Yanniv Dorone — Director
- Matthew McManus — Director
- Chenny Zhang — Director
- Sebastian Palluk — Executive Officer
- Filing: Form D/A (amended) filed 2025-12-10
- Amount sold: $46.45M
- Industry group: Biotechnology
- Based: EMERYVILLE, CALIFORNIA
- Entity type: Corporation
We'll show it in your MentionFox inbox when Ansa Biotechnologies, Inc. raises, hires or launches. No email unless you switch it on.
Watch Ansa Biotechnologies, Inc. →Want the whole picture on Ansa Biotechnologies, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ansa Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ansa Biotechnologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Ansa Biotechnologies, Inc.'s own filings with the SEC. The people those filings name are on the team page.